Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

PURPOSE: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after induction. However, there is significant clinical variability in the duration, dosing, and timing of maintenance therapy aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellini, Bruna, Madison, Russell W., Childress, Merrida A., Miller, Shoshana T., Gjoerup, Ole, Cheng, Jason, Huang, Richard S.P., Krainock, Michael, Gupta, Pratyush, Zou, Wei, Shames, David S., Moshkevich, Solomon, Ballinger, Marcus, Liu, Minetta C., Young, Amanda, Srivastava, Minu K., Oxnard, Geoffrey R., Socinski, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643998/
https://www.ncbi.nlm.nih.gov/pubmed/37702716
http://dx.doi.org/10.1158/1078-0432.CCR-23-1578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643998/
https://www.ncbi.nlm.nih.gov/pubmed/37702716
http://dx.doi.org/10.1158/1078-0432.CCR-23-1578

Ejemplares similares